IN2014CN03130A - - Google Patents

Info

Publication number
IN2014CN03130A
IN2014CN03130A IN3130CHN2014A IN2014CN03130A IN 2014CN03130 A IN2014CN03130 A IN 2014CN03130A IN 3130CHN2014 A IN3130CHN2014 A IN 3130CHN2014A IN 2014CN03130 A IN2014CN03130 A IN 2014CN03130A
Authority
IN
India
Prior art keywords
represent
npt
preventive
formula
iib
Prior art date
Application number
Inventor
Masanori Miura
Daisuke Kaga
Susumu Watanuki
Shunichiro Hachiya
Takao Okuda
Ippei Sato
Mai Isomura
Kazuhiro Terai
Yoh Terada
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of IN2014CN03130A publication Critical patent/IN2014CN03130A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C07D333/80Seven-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
    • C07F9/655354Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Abstract

The objective of the present invention is to provide a compound having inhibitory activity against an intestinal phosphate transporter (NPT IIb) and useful as an active ingredient in a hyperphosphatemia therapeutic agent and/or preventive. A thiophene compound represented by formula (I) may be used as a hyperphosphatemia therapeutic agent and/or preventive having NPT IIb inhibitory activity. (In the formula R each represent H or a lower alkyl or the like L each represent a lower alkyl or the like X represents CH or O X each represent CH or N k is 1 3 and n is 0 1.)
IN3130CHN2014 2011-10-27 2012-10-25 IN2014CN03130A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011236533 2011-10-27
PCT/JP2012/077660 WO2013062065A1 (en) 2011-10-27 2012-10-25 Aminoalkyl-substituted n-thienyl benzamide derivative

Publications (1)

Publication Number Publication Date
IN2014CN03130A true IN2014CN03130A (en) 2015-07-03

Family

ID=48167891

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3130CHN2014 IN2014CN03130A (en) 2011-10-27 2012-10-25

Country Status (16)

Country Link
US (1) US9062032B2 (en)
EP (1) EP2772490B1 (en)
JP (2) JP2013107880A (en)
KR (1) KR101941048B1 (en)
CN (1) CN103906741B (en)
AR (1) AR088563A1 (en)
AU (1) AU2012329913A1 (en)
CA (1) CA2853688C (en)
EA (1) EA023955B1 (en)
ES (1) ES2585415T3 (en)
IL (1) IL232230A0 (en)
IN (1) IN2014CN03130A (en)
MX (1) MX342521B (en)
PL (1) PL2772490T3 (en)
TW (1) TW201323419A (en)
WO (1) WO2013062065A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3150582A1 (en) 2012-10-02 2017-04-05 Gilead Sciences, Inc. Inhibitors of histone demethylases
US9499553B2 (en) 2013-03-13 2016-11-22 Chugai Seiyaku Kabushiki Kaisha Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same
SI2975030T1 (en) 2013-03-13 2020-10-30 Chugai Seiyaku Kabushiki Kaisha Dihydropyridazine-3,5-dione derivative
TWI594975B (en) * 2013-04-24 2017-08-11 第一三共股份有限公司 Compound having di-carboxylic moiety
SG11201600891UA (en) 2013-08-08 2016-03-30 Galapagos Nv Thieno[2,3-c]pyrans as cftr modulators
WO2015064532A1 (en) * 2013-10-30 2015-05-07 第一三共株式会社 Morpholine compound
WO2015153498A1 (en) * 2014-03-31 2015-10-08 Epitherapeutics, Aps Inhibitors of histone demethylases
WO2016026372A1 (en) * 2014-08-22 2016-02-25 江苏恒瑞医药股份有限公司 Thienocycloalkyl or thienoheterocyclic derivatives, preparation method thereof and use thereof in medicine
CN107072993B (en) 2014-09-12 2021-02-12 中外制药株式会社 Pharmaceutical containing sodium-dependent phosphate transporter inhibitor
ES2864277T3 (en) 2014-09-26 2021-10-13 Daiichi Sankyo Co Ltd Salt of dicarboxylic acid compounds
CN105524053B (en) * 2014-10-19 2020-06-05 广东东阳光药业有限公司 Tetrahydrobenzothiophene compounds
TW201700458A (en) 2015-04-24 2017-01-01 第一三共股份有限公司 Method for producing dicarboxylic acid compound
CN107082773B (en) * 2016-02-16 2020-07-28 江苏恒瑞医药股份有限公司 Sulfate of intestinal 2B type sodium phosphate cotransporter inhibitor and crystal form thereof
ES2830444T3 (en) * 2016-08-15 2021-06-03 Lilly Co Eli Condensed thiophene derivatives useful as NaPi-IIb inhibitors
JOP20190080A1 (en) 2016-10-14 2019-04-11 Bayer Pharma AG Substituted 6-(1h-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof
CN109422723B (en) * 2017-08-25 2021-02-23 江苏恒瑞医药股份有限公司 Crystal form of intestinal 2B type sodium phosphate cotransporter inhibitor and preparation method thereof
CA3221186A1 (en) 2021-06-08 2022-12-15 Kenichi Sakai Formulation containing dihydropyridazine-3,5-dione derivative
AR126060A1 (en) 2021-06-08 2023-09-06 Chugai Pharmaceutical Co Ltd METHOD FOR PRODUCING DIHYDROPYRIDAZIN-3,5-DIONE DERIVATIVE
WO2023203254A2 (en) 2022-04-22 2023-10-26 Fundamental Pharma Gmbh Effective means to modulate nmda receptor-mediated toxicity

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002213048A1 (en) 2000-10-05 2002-04-15 Smith Kline Beecham Corporation Phosphate transport inhibitors
JP2007131532A (en) * 2001-09-28 2007-05-31 Kirin Brewery Co Ltd Compound for inhibiting delivery of phosphorus in living body and drug containing the same
JPWO2003048134A1 (en) 2001-12-05 2005-04-14 日本たばこ産業株式会社 Triazole compounds and pharmaceutical use thereof
EP1614676A4 (en) 2003-03-27 2009-03-25 Kirin Pharma Kk Compound inhibiting in vivo phosphorus transport and medicine containing the same
WO2006093518A2 (en) 2004-06-25 2006-09-08 Apath, Llc Thienyl compounds for treating virus-related conditions
CA2579089A1 (en) 2004-08-30 2006-03-09 Government Of The United States Of America As Represented By The Secreta Ry Department Of Health And Human Services Inhibition of viruses using rnase h inhibitors
WO2006044826A2 (en) 2004-10-20 2006-04-27 Compass Pharmaceuticals Llc Thiophens and their use as anti-tumor agents
KR101343399B1 (en) * 2008-01-08 2013-12-19 퍼듀 퍼머 엘피 Proline analogs as ligands for cannabinoid receptors for the treatment of pain
JP5617919B2 (en) 2010-04-28 2014-11-05 アステラス製薬株式会社 Tetrahydrobenzothiophene compound
JP5823514B2 (en) 2010-07-07 2015-11-25 アーデリクス,インコーポレーテッド Compounds and methods for inhibiting phosphate transport
WO2012006473A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2590965B1 (en) 2010-07-07 2016-04-20 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2590510B1 (en) 2010-07-07 2016-09-28 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2591354B1 (en) 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport

Also Published As

Publication number Publication date
EA201490875A1 (en) 2014-09-30
WO2013062065A1 (en) 2013-05-02
BR112014010169A2 (en) 2017-04-25
MX342521B (en) 2016-10-03
CA2853688C (en) 2018-06-12
PL2772490T3 (en) 2016-11-30
JP2013107880A (en) 2013-06-06
KR101941048B1 (en) 2019-01-22
KR20140096322A (en) 2014-08-05
MX2014005090A (en) 2015-02-12
CN103906741B (en) 2016-01-20
EP2772490A1 (en) 2014-09-03
US9062032B2 (en) 2015-06-23
US20150031727A1 (en) 2015-01-29
IL232230A0 (en) 2014-06-30
EP2772490A4 (en) 2015-01-21
TW201323419A (en) 2013-06-16
JP6020460B2 (en) 2016-11-02
EA023955B1 (en) 2016-07-29
JPWO2013062065A1 (en) 2015-04-02
CA2853688A1 (en) 2013-05-02
AR088563A1 (en) 2014-06-18
AU2012329913A1 (en) 2014-05-22
ES2585415T3 (en) 2016-10-05
EP2772490B1 (en) 2016-04-06
CN103906741A (en) 2014-07-02

Similar Documents

Publication Publication Date Title
IN2014CN03130A (en)
IN2015MN00405A (en)
TN2011000400A1 (en) Inhibitors of beta-secretase
BR112014017749A8 (en) 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF
MX356342B (en) Endoparasite control agent and use thereof.
MX348422B (en) Inhibitors of arginase and their therapeutic applications.
MX336381B (en) Boronates as arginase inhibitors.
IN2014CN00712A (en)
MX2013001805A (en) 2-(arylamino)-3h-imidazo[4,5-b]pyridine-6-carboxamide derivatives and their use as mpges-1 inhibitors.
AU2012214029A8 (en) Rorgammat inhibitors
TN2014000122A1 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
CL2009000650A1 (en) Compounds derived from amino-pyrazine, kinase-pi 3 inhibitors; pharmaceutical composition; and use for the treatment of inflammatory or allergic conditions, such as respiratory diseases, rheumatoid arthritis, ulcerative colitis, among others.
TN2015000245A1 (en) Heterocyclic compound
GEP20146197B (en) New compounds
EA201291121A1 (en) TETRAHYDROBENZOTIOPHEN COMPOUNDS
MX351812B (en) Pyridone derivative.
MA35402B1 (en) Pesticide compositions and related processes
UA108926C2 (en) LibreOfficeKINASE PYRROLO[2,3-DEPENDENT INHIBITORS
MY172924A (en) Neprilysin inhibitors
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
IN2014CN04204A (en)
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
IN2012DN02502A (en)
IN2014CN04449A (en)
IN2013CN01335A (en)